Dr Reddy’s Lab announces commercial launch of anti-COVID drug 2DG
With Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major Governments as well as private hospitals across the country.
FollowDr Reddy’s Laboratories today announced the commercial launch of 2-deoxy-D-glucose(2-DG), a medicine developed by the Defence Research and Development Organisation (DRDO) for the treatment of Covid-19 patients.
The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.
Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
With Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major Governments as well as private hospitals across the country, Hyderabad based Pharmaceutical giant Dr Reddy Labs said in a release here.
2-DG manufactured by Dr Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DGTM.
In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India and with a subsidized rate offered to Government Institutions.
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s. 2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe Covid-19 patients as an adjunct therapy to the existing standard of care.
Dr G Satheesh Reddy, Secretary Department of Defence (R&D) and Chairman, DRDO said: “We are pleased to have worked closely with our long-term industry partner Dr Reddy's Laboratories for testing 2-DG as a therapeutic application in treatment of Covid-19 patients.
DRDO has been contributing to the fight against Covid-19 pandemic with its spin off technologies."
Dr Reddy Laboratories Chairman Satish Reddy said, “2-DG is yet another addition to our Covid-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine.
We are extremely pleased to have partnered with DRDO in our collective fight against the Covid-19 pandemic,” he said.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona
